Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Fuso Pharmaceutical Industries, Ltd.. A complete text table follows the diagram.
Dialysis-related generics lifted sales 5.0%, but costs and an JPY8.744B litigation payment turned operating cash flow deeply negative.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Net Sales | 1 | 31.2B | Reported interim top line |
| Operating profit | 2 | 1.2B | 4.0% operating margin |
| Operating costs & expenses | 2 | 30.0B | Arithmetic residual to reported operating profit |
| Profit before tax | 3 | 1.1B | Reported pretax result |
| Net non-operating cost | 3 | 145M | Arithmetic bridge to reported pretax profit |
| Net profit attributable to owners | 4 | 831M | Reported parent-company result |
| Tax, attribution & other | 4 | 271M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Net Sales | Operating profit | 1.2B |
| Net Sales | Operating costs & expenses | 30.0B |
| Operating profit | Profit before tax | 1.1B |
| Operating profit | Net non-operating cost | 145M |
| Profit before tax | Net profit attributable to owners | 831M |
| Profit before tax | Tax, attribution & other | 271M |